Cimzia approved for non-radiographic axial spondyloarthritis

FDA approved Cimzia certolizumab pegol to treat non-radiographic axial spondyloarthritis. FDA said the drug, from UCB S.A. (Euronext:UCB), is the first approved for the indication.

Cimzia, a pegylated humanized antibody fragment against TNFα, is also approved in the U.S. to treat Crohn's disease, rheumatoid arthritis, active ankylosing spondylitis and plaque psoriasis...